Bezafibrate is a medicine used to help lower high levels of fat in your blood. It works by reducing the amount of cholesterol and triglycerides, which are types of fats that can build up in your arteries. This helps protect your heart health.
Every report comes from a Lived member, sent anonymously.
Have you tried Bezafibrate for Biliary Cirrhosis?
Bezafibrate is a prescription lipid-lowering medicine from the fibrate family. Its main job is to lower triglycerides, a type of fat carried in the blood, when they are very high, and it also tends to raise HDL cholesterol (the "good" cholesterol). In the UK it is licensed for severe high triglycerides, with or without low HDL, and for mixed high cholesterol and triglycerides when a statin cannot be used or is not tolerated. It is meant to go alongside diet, physical activity, weight management and treatment of conditions that push blood fats up, such as poorly controlled diabetes or an underactive thyroid. Bezafibrate is not approved by the FDA and is not sold in the United States. It is available in the UK and a number of other countries, where it is sold as Bezalip Mono (a once-daily tablet) and under generic names. In the US, the fibrates prescribed for similar purposes are fenofibrate and gemfibrozil. Liver specialists also use bezafibrate off-label for primary biliary cholangitis (PBC), an autoimmune disease that slowly damages the small bile ducts inside the liver. It is added to ursodeoxycholic acid (ursodiol), the standard first treatment, when liver blood tests have not improved enough on ursodiol alone. It has also been studied for the persistent itch that bile duct diseases can cause.
Bezafibrate switches on PPARs (peroxisome proliferator-activated receptors), proteins inside liver and other cells that control how the body handles fat. One effect is that enzymes called lipoprotein lipases become more active. These enzymes break down the triglyceride-rich particles that carry fat through the bloodstream, so triglyceride levels fall. Some of the material released in that process is used to build HDL particles, which is why HDL usually rises. Bezafibrate also reduces the amount of cholesterol the liver makes and helps the liver clear LDL cholesterol (the "bad" cholesterol) from the blood. Bezafibrate also changes the makeup of bile, the digestive fluid the liver produces. That effect, along with its action on PPARs, is part of why it has been tried in bile duct diseases such as PBC. How exactly it improves liver tests and itching in those conditions is not fully worked out.
Bezafibrate comes as tablets in two forms. The standard 200 mg tablet is usually taken three times a day. The 400 mg modified-release tablet releases the medicine slowly and is taken once a day, in the morning or at night. Either form is swallowed whole with water after a meal. People prone to stomach upset may start on a lower dose that is built up over five to seven days. The kidneys clear bezafibrate from the body, so kidney function shapes which tablet is used. The once-daily 400 mg tablet is not used when creatinine clearance (an estimate of how well the kidneys filter blood) is below 60 ml/min, and the UK label advises against it after about age 70, because kidney function is usually lower by then. People with reduced kidney function may instead take the 200 mg tablet at a lower daily dose set from their kidney test results. Bezafibrate is not used at all by people on dialysis or with very severe kidney failure. In PBC studies, the dose was 400 mg a day taken alongside ursodiol. For that use, the dose and monitoring plan come from the liver specialist.
The most common side effects are digestive: stomach upset, bloating, nausea, diarrhea or constipation, and a reduced appetite. These are usually mild. Headache, dizziness, itching, rash, hair thinning and extra sensitivity of the skin to sunlight are less common, and erectile dysfunction has been reported. Because dizziness can occur, it makes sense to see how the medicine affects you before driving. Muscle problems are the side effect to know about. Fibrates can cause muscle pain, cramps, tenderness or weakness, and very rarely rhabdomyolysis, a severe breakdown of muscle tissue that can damage the kidneys. The risk is higher with reduced kidney function, age over 65, an underactive thyroid, heavy drinking, a past muscle reaction to a cholesterol medicine, or a statin taken at the same time. Unexplained muscle pain or weakness should be reported to the prescriber right away. A blood test for creatine kinase (CK), an enzyme released from damaged muscle, helps decide whether bezafibrate needs to stop. Bezafibrate can rarely lead to gallstones, and pancreatitis (inflammation of the pancreas) has also been reported rarely. Severe or persistent pain in the upper abdomen should be checked by a clinician the same day. Very rarely, serious skin reactions with widespread blistering or peeling have occurred, and these need urgent medical assessment.
Taking bezafibrate together with a statin increases both the chance and the severity of muscle damage. The combination is sometimes used with careful monitoring, but it is avoided in people who already have risk factors for muscle problems, such as reduced kidney function, older age or an underactive thyroid. Bezafibrate strengthens the effect of warfarin and similar blood thinners, which raises the risk of bleeding. The UK label advises reducing the blood thinner dose, by up to half, and checking the INR (international normalized ratio, a blood test of how long blood takes to clot) more often when bezafibrate is started. It can also add to the effect of insulin and other diabetes medicines, so blood sugar may need closer watching for a short time after starting. Bile acid binding resins such as colestyramine (cholesterol-lowering powders that work in the gut) block its absorption, so the two should be taken at least two hours apart. People who have had an organ transplant and take medicines to suppress the immune system have had reversible drops in kidney function, so their kidney tests are watched closely. Bezafibrate is not used by people with significant liver disease (other than the fatty liver that often comes with high triglycerides), gallbladder disease, nephrotic syndrome (a kidney condition in which protein leaks into the urine) or a previous light-sensitivity reaction to a fibrate. Its use in PBC is a separate, off-label decision by a liver specialist, who weighs the stage of the liver disease. It is not recommended during pregnancy or for people who could become pregnant and are not using contraception, and its safety during breastfeeding has not been established.
Triglyceride levels usually respond quickly, though improvement can continue over several weeks. Blood tests for lipids, kidney function and liver function are repeated after starting and then at intervals. If triglycerides have not improved enough after three to four months, the UK label advises stopping bezafibrate and considering another approach. Lower triglycerides and higher HDL do not automatically mean a longer life. Fibrates may reduce heart events, but they have not been shown to lower deaths from all causes. In a large trial of people with existing heart disease, bezafibrate improved HDL and triglycerides but produced only a trend toward fewer heart attacks overall, with a possible benefit in people whose triglycerides were high that still needed confirming. For lowering heart risk, statins usually come first, and bezafibrate is chosen mainly when triglycerides are the main problem or a statin cannot be used. In PBC, the aim is to bring liver blood tests, especially alkaline phosphatase (an enzyme that rises when bile flow is impaired), back toward normal. In a two-year trial of people who had not responded well enough to ursodiol, 31% of those who added bezafibrate reached fully normal liver tests, compared with none on placebo, and itching, fatigue and measures of liver stiffness also improved. Muscle aches were more common (20% versus 10%), and creatinine rose slightly. Whether these improvements lead to fewer liver complications or longer survival is not yet known. In a three-week trial in people with troublesome itch from PBC or primary sclerosing cholangitis (another bile duct disease), 45% on bezafibrate had their itch at least halved, compared with 11% on placebo. Newer licensed second-line medicines for PBC, elafibranor and seladelpar, now give specialists other options to weigh.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Bezafibrate, what you've noticed, or ask the community a question.